gallstones and semaglutide Gallstones: Safety Facts semaglutide and gallstones semaglutide and

Retatrutide delivered weight loss and osteoarthritis pain relief in the TRIUMPH-4 phase 3 trial, December 2025

Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used

Your suit may have grounds for award if you have taken Ozempic, Wegovy, Rybelsus or another form of semaglutide and: Have developed gallbladder disease Are suffering from intestinal blockage Developed gastroparesis Are suffering from frequent or constant: Vomiting Nausea Abdominal pain Were ready to speak with you about your case

Evidence also suggestions that it may offer some protection from type 2 diabetes, blood sugar levels, and weight gain

Once administered, semaglutide remains active in the body for an extended period, influencing appetite regulation throughout the week

This is why many prescribers recommend sticking with your dose for at least 4 weeks before making any adjustmentsgiving your system time to find its equilibrium